Clinical Trials
31 trialsTesting the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
National Cancer Institute (NCI)
TroFuse-019
Merck Sharp & Dohme LLC
Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer
Alliance for Clinical Trials in Oncology
AcceleRET-Lung
Hoffmann-La Roche
BREC
Spanish Lung Cancer Group
MODEL
Intergroupe Francophone de Cancerologie Thoracique
EPIC
University of Turin, Italy
Polyglutamate Paclitaxel Compared With Gemcitabine or Vinorelbine in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer
CTI BioPharma
Nivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer
Incyte Corporation
Clinical Study of Chinese Medicine Plus Chemotherapy Maintenance in Advanced Non Small Cell Lung Cancer
Shanghai University of Traditional Chinese Medicine
Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer
Alliance for Clinical Trials in Oncology
Chemotherapy or Observation in Treating Patients With Early Stage Non-Small Cell Lung Cancer
Alliance for Clinical Trials in Oncology
The Comparative Study on Rh-Endostatin (Endostar®) Continuous Intravenous Infusion and Routine i.v in Combination With GP Regimens for Phase III B/IV Squamous Cell Lung Cancer and Biological Markers Exploration.
Jiangsu Simcere Pharmaceutical Co., Ltd.
Vinorelbine and/or Gemcitabine in Treating Older Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
National Cancer Institute (NCI)
ZD 1839 Plus Combination Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Surgery With or Without Preoperative Chemotherapy in Treating Patients With Resectable Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Hospitalization Rates of Patients With Non-Small Cell Lung Cancer Treated With Gemcitabine and Either Cisplatin or Carboplatin
National Cancer Institute (NCI)
Vinorelbine, Gemcitabine, and Docetaxel Compared With Paclitaxel and Carboplatin in Treating Patients With Advanced Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Gemcitabine in Combination With Either Cisplatin or Carboplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Combination Chemotherapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
Fox Chase Cancer Center
Chemotherapy and Radiation Therapy With or Without Efaproxiral in Treating Patients With Stage III Non-Small Cell Lung Cancer
Spectrum Pharmaceuticals, Inc
Gemcitabine With or Without CI-994 in Treating Patients With Advanced Non-small Cell Lung Cancer
Pfizer
Prinomastat and Combination Chemotherapy in Treating Patients With Metastatic or Recurrent Non-small Cell Lung Cancer
Pfizer
Chemotherapy Plus Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Non-small Cell Lung Cancer That Cannot Be Surgically Removed
European Organisation for Research and Treatment of Cancer - EORTC
Combination Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Vinorelbine/Gemcitabine Versus Vinorelbine/Carboplatin in Advanced Non-small Cell Lung Cancer
The Norwegian Lung Cancer Study Group
Gemcitabine and Carboplatin Followed By Docetaxel in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Case Comprehensive Cancer Center
Study of Paclitaxel, Carboplatin, and Gemcitabine Versus Gemcitabine and Vinorelbine for Non-Small Cell Lung Cancer
SCRI Development Innovations, LLC
GILT Docetaxel - Non-Small Cell Lung Cancer
Sanofi
Phase III Study of Gemcitabine Compared With UFT in Patients With Completely Resected Pathological Stage IB-IIIa Non Small Cell Lung Cancer
West Japan Thoracic Oncology Group